Interim report January - September 2003

INTERIM REPORT JANUARY - SEPTEMBER 2003 · Turnover during the first nine months amounted to SEK 427.8 (369.5) million, of which SEK 145.1 (116.1) million was during the third quarter. · Operating income amounted to SEK 452.0 (26.1) million during the first nine months. Adjusted for items affecting comparability in 2003 and the one-time revenue in 2002, operating income amounted to SEK -10.2 (4.4) million. · Net income after tax for the nine-month period amounted to SEK 457.1 (18.8) million. Adjusted for items affecting comparability in 2003 and the one-time revenue in 2002, net income amounted to SEK -5.1 (3.2) million. · Earnings per share amounted to SEK 18.42 (0.76). · All patients in a study on the product SubQ treated. · First patient included in a study on DEFLUX in Japan. Queries should be addressed to: Bengt Ågerup, President and CEO, tel: +46(0)18-474 90 00 or +46(0)70-974 90 25. Fredrik Hallstan, Manager of Investor Relations and Corporate Communications, tel: +46(0)18-474 90 15 or +46(0)70-974 90 15. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/17/20031017BIT00310/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/10/17/20031017BIT00310/wkr0002.pdf The full report

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.

Subscribe